ClinMed Pharma
EN
DE PL FR
MENU
X
⤺
Relapsed and Refractory Classical Hodgkin Lymphoma articles

Relapsed and Refractory Classical Hodgkin Lymphoma

The management of relapsed and refractory classic Hodgkin lymphoma (HL) has changed substantially since the approval of brentuximab vedotin (BV) and the checkpoint inhibitors nivolumab and pembrolizumab. READ MORE
Simplifying Risk-Based Monitoring articles

Simplifying Risk-Based Monitoring

A few years have elapsed since ICH added the E6 (R2) addendum to its Good Clinical Practice Guidelines. READ MORE
World’s first ‘Darwinian’ cancer drug programme aims to deliver step change in cancer treatment articles

World’s first ‘Darwinian’ cancer drug programme aims to deliver step change in cancer treatment

We at Clinmed Pharma were excited when we read this. READ MORE
Prostate cancer mutation found to triple risk of death articles

Prostate cancer mutation found to triple risk of death

A fantastic example of genetic research. We hope this provides more treatments options to prostate cancer patients expressing a mutation... READ MORE

Request for information

Learn more

Request for proposal

Learn more
ABOUT US
Meet the Team Our Mission Our Values Our Global Reach Our Customers
SERVICES
Clinical Development Clinical Operations Biostatistics and Data Management Regulatory Pharmacovigilance Clinical Quality Temporary Resourcing Solutions Real-World Evidence Market Access
THERAPEUTIC AREA EXPERTISE
Oncology & Haematology Orthopaedics & Wound Healing Central Nervous System (CNS) Women’s & Male Health Immunology and Cancer Immunotherapy Respiratory Medicine Cardiovascular Dermatology Metabolic & Endocrinology Biosimilars Rare & Orphan Disease Gastroenterology Ophthalmology Infectious Diseases
NEWSROOM Announcements Blog Videos Articles
Join Us Contact Request for proposal Request for information